PregLem SA is a Swiss-based specialty biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s ....
Location: Switzerland
Employees: 11-50
Total raised: $58.25M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.12.2007 | Series B | $32.21M | - |
| 27.06.2007 | Series A | $26.04M | - |
Mentions in press and media 5
| Date | Title | Description |
| 25.02.2016 | How to raise CHF100 million | |
| 27.02.2012 | European Commission approves Esmya® for the pre-operative treatment of uterine fibroids (myomas) | Gedeon Richter Plc. (“Richter”) announces today that the European Commission (EC) has granted marketing authorization to Esmya® 5mg tablet as pre-operative treatment of moderate to severe symptoms of uterine fibroids. This decision follows... |
| 27.12.2011 | PregLems first drug on the way to the market | |
| 04.12.2007 | PregLem annoucnes CHF 36 million Series B funding and new licensing agreement with HRA Pharma | PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds for female reproductive medicine, today announced the closing of a CHF 36 million Series B financing r... |
| 27.06.2007 | PregLem announces CHF 32 million Series A funding from leading European VC firms and license agreement with Ipsen | PregLem today announced the closing of a CHF 32 million Series-A financing round (€20 million). The Series A financing round was led by Sofinnova Partners, and co-led by NeoMed Management and MVM Life Science Partners LLP. Concurrently, Pre... |